GlassScriptPhysician profile
Patrick D Kuhlman
NPI 1386064640
$4,020.11
in general payments reported to CMS, 2019-2025
46 companies · $992 in 2025
The $992 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $95.00 · 2021: $125 · 2022: $610 · 2023: $1,074 · 2024: $924 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,989.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $610.15 | 2021-2025 | Imfinzi, Tagrisso, Enhertu |
| Seagen INC. | $330.22 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Novartis Pharmaceuticals Corporation | $268.11 | 2023-2025 | |
| Galvanize Therapeutics, INC | $222.32 | 2023 | Aliya System |
| Gilead Sciences, INC. | $189.89 | 2023-2025 | Trodelvy |
| Incyte Corporation | $175.05 | 2024-2025 | Pemazyre, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $174.11 | 2022-2025 | Opdualag, Opdivo |
| Janssen Biotech, INC. | $172.74 | 2023-2025 | Tecvayli, Darzalex, Erleada |
| Pfizer INC. | $158.41 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.08 | 2019-2025 | Fruzaqla, Livtencity |
| Boston Scientific Corporation | $144.18 | 2022 | |
| Astellas Pharma US INC | $127.98 | 2023-2025 | Padcev, Xtandi, Cresemba |
| Stemline Therapeutics INC. | $122.63 | 2022 | |
| Genmab U.S., INC. | $121.87 | 2025 | Epkinly |
| Daiichi Sankyo INC. | $107.23 | 2023-2025 | Enhertu, Injectafer |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $72.78 | 2023-2025 | Reblozyl, Pomalyst |
| Glaxosmithkline, LLC. | $70.07 | 2025 | Ojjaara, Blenrep |
| Array Biopharma INC | $57.03 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Genentech USA, INC. | $56.93 | 2023-2025 | Venclexta |
| Genzyme Corporation | $52.77 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.60 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $51.90 | 2024 | Keytruda |
| Adc Therapeutics America, INC. | $46.95 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.86 | 2024-2025 | Gilotrif |
| Acrotech Biopharma INC. | $44.48 | 2023-2025 | Beleodaq |
| Rigel Pharmaceuticals, INC. | $35.83 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Karyopharm Therapeutics INC. | $24.82 | 2025 | Xpovio |
| Foundation Medicine, INC. | $24.25 | 2023 | |
| Azurity Pharmaceuticals, INC. | $23.50 | 2025 | Danziten |
| Caris Mpi, INC. | $22.09 | 2025 | Mi Cancer Seek |
| Abbvie INC. | $20.04 | 2025 | |
| Cti Biopharma Corp. | $19.20 | 2023 | Vonjo |
| Kite Pharma, INC. | $18.90 | 2023 | Yescarta |
| Recordati_rare_diseases_inc. | $18.73 | 2025 | Enjaymo |
| Biocryst US Sales Co., LLC | $18.24 | 2024 | Orladeyo |
| Beigene USA, INC. | $17.76 | 2024 | Brukinsa |
| Emd Serono, INC. | $17.51 | 2025 | |
| Eisai INC. | $16.35 | 2024 | |
| G1 Therapeutics, INC. | $16.16 | 2023 | Cosela |
| Syndax Pharmaceuticals, INC. | $16.04 | 2025 | |
| Kyowa Kirin, INC. | $15.88 | 2024 | Poteligeo |
| Tersera Therapeutics LLC | $15.28 | 2025 | Xermelo |
| Morphosys, US INC. | $14.39 | 2023 | Monjuvi |
| Melinta Therapeutics, LLC | $14.32 | 2025 | Rezzayo |
| Regeneron Healthcare Solutions, INC. | $14.29 | 2024 | Libtayo |
| Exelixis INC. | $13.19 | 2024 | Cabometyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Kuhlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.